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A B S T R A C T
Syphilis and HIV are both transmitted sexually and have emerged as important co-pathogens with
reciprocal augmentation in transmission and disease progression. HIV-positive patients tend to
experience more aggressive symptomatology due to syphilis and are at greater risk of developing
neurological disease. Similarly, standard therapy for syphilis may be inadequate in HIV-positive
individual suggesting intensiﬁed treatment regimens may be required along with close follow-up. We
report here the case of a 50-year-old HIV-positive male presenting with an unusual constellation of
neurological ﬁndings. Although he had been treated appropriately 10 years previously for primary
syphilis, investigations revealed multiple current intracranial gummas. Treatment with high-dose
intravenous penicillin G resulted in clinical and radiographic resolution. Given the broad differential for
HIV-positive patients presenting with neurological symptoms, the clinician must maintain a high index
of suspicion for syphilis known for its varied and at times unusual manifestations. Further, prior
treatment of syphilis does not ensure cure and so syphilis must be considered irrespective of treatment
history.
 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Although syphilis had its origins in the New World,1,2 this
sexually transmitted disease now has a global distribution. In
many industrialized nations, rates of infectious syphilis remained
low through the 1980’s,3 but began to rise around the turn of the
century.4–7 In Canada, the rate increased nearly 10-fold from 0.4
cases per 100 000 in 1997 to 3.5 per 100 000 in 2004.4 Themajority
of recent outbreaks of infectious syphilis in industrialized
countries, as well as one report from China, have been among
menwho have sex withmen (MSM).8,9 In the developing countries
of sub-Saharan Africa and Asia, syphilis appears prevalent in the
general population ranging from 1.6% to 19%.10–14
HIV and syphilis are both transmitted sexually and have
emerged as important co-pathogens. In several developed
countries, the prevalence of HIV among patients with syphilis
has ranged from 15.7% to 43%,15–17 and as high as 64–90%.15 These
high rates of co-infection are not surprising given the reciprocal
effects of the two pathogens on transmission and disease
progression. Primary syphilis results in genital ulcers (chancres),
which facilitate transmission of HIV.18 Syphilis has also been
shown to increase HIV viral loads in both blood and genital ﬂuids,
which may further increase the risk of HIV transmission as well as* Corresponding author. Tel.: +1 613 737 8899x73917; fax: +1 613 737 8164.
E-mail address: pmacpherson@ottawahospital.on.ca (P. MacPherson).
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doi:10.1016/j.ijid.2009.11.033the rate of progression to immune deﬁciency.19,20 Similarly, HIV
facilitates the spread of syphilis. Multiple and persistent syphilitic
chancres have been reported in patients with HIV infection.21,22
Those with HIV also tend to experience more aggressive disease
due to syphilis, particularly as CD4 counts decline,22 and are more
likely to have visceral involvement including neurosyphi-
lis.16,21,23,24 Indeed, those with a CD4 count less than 350 cells/
ml and a rapid plasma reagin (RPR) titer greater than 1:32 are
nearly 20-times more likely to have neurosyphilis compared to
HIV-negative individuals.24 Neurosyphilis may present in any of a
number of forms depending on disease stage, includingmeningitis,
meningovascular disease, parenchymal disease including general
paresis and tabes dorsalis, as well as gummatous lesions.
We report here the case of a 50-year-old HIV-positive male
treated for primary syphilis 10 years previously, who presented
withmultiple intracranial syphilitic gummas causing in an unusual
constellation of neurological symptoms.
2. Case report
A 50-year-old HIV-infected man presented to a tertiary care
center with a 1-month history of progressive right facial
anesthesia, right facial droop, decreased hearing in the right ear,
and pain in the right knee. There was a 6-month history of fatigue
but no other constitutional symptoms. The patient reported new
onset headaches within the last 2 weeks. Otherwise a review of
systems yielded no other ﬁndings.ses. Published by Elsevier Ltd. All rights reserved.
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declined antiretroviral therapy for personal reasons. At the time of
presentation, he had a CD4 count of 296 cells/ml and a viral load of
120 664 copies/ml. The patient had been treated for primary
syphilis in 1997with one intramuscular injection of 2.4  106 units
of benzathine penicillin G. At presentation, serologic testing for
syphilis revealed a reactive enzyme-linked immunoassay (EIA) and
a positive Treponema pallidum particle agglutination assay (TP-PA)
with an RPR titer of 1:2, ﬁndings not inconsistent with previously
treated disease. Serology for Toxoplasma was negative, while
Epstein–Barr virus IgG was positive. The patient had recently been
diagnosed with stage III anal intraepithelial neoplasia with plans
for resection.
On examination the patient was alert, oriented and appropriate,
and vital signs were within normal limits. Head and neck exam
revealed seborrheic dermatitis over the brow. Pupils were equal
and reactive to light with no evidence of Argyll–Robertson pupils.
Fundi were normal with no papilledema. Cranial nerves II–IV, VI,
and IX–XII were normal and symmetric bilaterally. Cranial nerve V
on the right showed decreased sensation in all three distributions.
Cranial nerve VII on the right showed an upper motor neuron
lesionwith facial droop and sparing of the forehead. Therewas also
subjective decreased hearing in the right ear. Neurological exam
showed decreased motor strength on right hip ﬂexion, while
sensation, coordination, and patellar and brachial reﬂexes were all
normal. Gait revealed a limp secondary to pain in the right knee
and decreased strength in the right hip.
Chest and cardiovascular examinations were unremarkable.
The abdominal exam was normal. A digital rectal exam showed no
evidence of prostate hypertrophy and no blood.
In terms of medications, the patient was taking co-trimoxazole
and bupropion daily, and olanzapine at night.
Neurological ﬁndings progressed over the next 2 weeks with
increased weakness on right hip ﬂexion and the development of
reduced motor strength on right knee extension. The right facial
droop also became more prominent.
A computed tomography (CT) scan of the brain done
immediately on presentation revealed no evidence of stroke.
Subsequent magnetic resonance imaging (MRI) revealed the
presence of multiple space occupying lesions (Figures 1 and 2).
One lesion (28 mm diameter) was identiﬁed at the emergence of
cranial nerve V from the right brain stem and extended into and
obliterated Meckel’s cave (Figure 2A). A 16 mm dural-based mass
at the junction of the high left anterior convexity and falx cerebri
was noted (Figures 1A and 2B), along with three dural-basedFigure 1.MRI post-contrast coronal spin-echo, inversion recovery and diffusion-weighte
the junction of the high left anterior convexity and falx cerebri. (B) Three dural-based m
17 mm (left-side posterior). These three lesions were immediately adjacent to the supmasses at the cerebral vertex (16, 17, and 17 mm) (Figures 1B and
2C–E). These lesions were immediately adjacent to, but did not
invade, the superior sagittal sinus.
The differential diagnosis at this point includedmeningiomas as
suggested by the MRI images, and Schwannoma given the lesion
extending into Meckel’s cave. Also high on the differential was
metastatic cancer in view of the known anal intraepithelial
neoplasm. There was also a high degree of suspicion for syphilitic
gummas. Imaging was not consistent with lymphoma, while brain
abscesses, Toxoplasma and progressive multifocal leukoencepha-
lopathy were considered unlikely.
Lumbar puncture and analysis of the cerebrospinal ﬂuid (CSF)
revealed a lymphocytic pleocytosis with a white blood count of
143  106 cells/l (92% lymphocytes). CSF glucose was low at 1.9
mmol/l (30% serum glucose) and total protein elevated at 1.19 g/l.
The venereal disease reference laboratory test (VDRL) in the CSF
was non-reactive, but ﬂuorescent treponemal antibody absorption
(FTA-ABS) was reactive. Cultures of the CSF for bacteria,
mycobacteria, and fungi were all negative. Pathological analysis
of the CSF revealed no malignant cells.
Biopsies of the skull and underlying dura revealed ill-deﬁned
granulomas consisting of lymphocytes, plasma cells and macro-
phages, with no evidence of necrosis. Stains for acid-fast bacteria
and fungi were negative. Steinert and Warthin–Starry stains for
spirochetes demonstrated the presence of appropriately sized
corkscrew-shaped organisms consistent with T. pallidum.
The diagnosis of intracerebral syphilitic gummas was thus
conﬁrmed and therapy consisting of intravenous penicillin G 24
million units daily divided into six doses was given for a total of 21
days.
Within 1 week of initiating treatment, the patient began to
show improvement with increased sensation on the right side of
his face, partial resolution in the right facial droop, complete
resolution of his right knee pain, and increased motor strength in
both right hip ﬂexion and knee extension. Within 4 weeks of
treatment, therewas complete resolution of all symptomswith the
exception of some mild persistent numbness on the right side of
his face.
Follow-up MRI images 9 months later showed dramatic
improvement, with no enhancing intracranial lesions
(Figure 2F–J). Serum syphilis serology 6 months post-treatment
showed, as expected, a persistently reactive EIA and TP-PA. The
RPR had converted to non-reactive. Repeat lumbar puncture at 1
year post-treatment revealed no white cells and normal glucose
and protein levels (glucose 3.0 mmol/l, 54% of serum glucose;d images obtained through the brain. (A) A 16.2 mm diameter dural-based mass at
asses at the cerebral vertex: 17 mm (right-sided), 16 mm (left-sided anterior), and
erior sagittal sinus but did not appear to invade the sinus.
Figure 2.MRI post-contrast sagittal spin-echo, inversion recovery and diffusion-weighted images obtained through the brain. Images (A)–(E)were obtained before treatment,
while images (F)–(J) were 9 months post-treatment and show resolution of the gummatous lesions. A 28  11 mm lesion was seen near the right ﬁfth cranial nerve
obliteratingMeckel’s cave on the right side (A). A dural-basedmass, 16.2 mm in diameter, was identiﬁed at the junction of the high left anterior convexity and falx cerebri (B).
There were two dural-based lesions at the vertex, the left lesion measuring 16 mm (C) and the right measuring 17 mm (D). Posterior to these was a left parasagittal dural-
based lesion measuring 17 mm (E).
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the FTA-ABS had converted to non-reactive.
Following treatment of his syphilis, the patient started
antiretroviral therapy. Baseline CD4 count and viral load were
170 cells/ml and 76 634 copies/ml, respectively. Nine months after
initiating therapy, the patient’s CD4 count had increased to 284
cells/ml and HIV viral load was suppressed to below the limit of
detection (<50 copies/ml). One year after presentation, the patient
was healthy and doing well.
3. Discussion
Syphilis has long been known for its protean and varied
manifestations. Treponema pallidum, the causative agent of
syphilis, is acquired through close sexual contact or by vertical
transmission frommother to child. Following sexual transmission,
syphilis progresses through a number of disease stages, beginning
with the primary ulcer or chancre at the site of inoculation. This is
followed by secondary syphilis during which time T. pallidum
spreads hematogenously through the body, usually resulting in
low grade fevers and rash. During this period, syphilis invades
virtually every organ of the body. In up to 40% of infected
individuals, T. pallidum invades the central nervous system where
it may remain asymptomatic or cause clinical meningitis or
meningovascular disease.25 Without treatment, syphilis settles
into a low-grade chronic infection. Gummatous lesions can appear
from 3 to 12 years after infection. Tertiary symptoms develop
anywhere from20 to 40 years after infection andmanifest as either
cardiac disease or parenchymal disease of the central nervous
system.25–27
Gummas consist of granulomatous inﬂammation.28–30 These
lesions most commonly affect skin or bone, but can involve any
organ.27 Cerebral gummas are rare and when described are often
located peripherally, proximal to the dura and pia.29–34 Cerebral
gummas act as space occupying lesions causing neurological signs
and symptoms ranging from seizures to cognitive dysfunction
depending on their location.26,30,32,35–40
Intracranial gummatous syphilis can be a diagnostic challenge,
perhaps even more so in the HIV-positive population where theselesions can be misinterpreted as Toxoplasma, brain abscess,
tuberculoma, or lymphoma. Other entities on the differential in
both the HIV-positive and –negative populations include sarcoi-
dosis, glioblastoma multiforme, cranial nerve neuromas, and
metastatic cancers. In the patient described here, Toxoplasma
was considered unlikely in view of the CD4 count and the pattern
of lesions being largely cortical and not favoring the basal ganglia,
as is often seen with toxoplasmosis.41 Similarly lymphoma, unlike
gummas, are often periventricular in location.30
Tests including CT, MRI, serology, CSF examination, polymerase
chain reaction (PCR), and biopsy are useful in establishing the
diagnosis of intracranial syphilitic gummas. CT scans reveal space
occupying lesions often surrounded by edema,29,30,33 while MRI
shows non-speciﬁc hypo-intense masses with T1 weighting and
hyper-intense images with T2 weighting.29,30,33 Biopsies cannot
conﬁrm the presence of T. pallidum per se, but silver staining
techniques may demonstrate the presence of spirochetes.42 PCR
when available ismore sensitive for detecting T. pallidum.28 Finally,
CSF examination and serological testing can support the diagnosis
of gummatous syphilis, although the sensitivity of the CSF VDRL for
patients with neurosyphilis is only about 70%.43 Elevated CSF
protein levels and a lymphocytic pleocytosis may be other clues
consistent with intracranial gummas.26,31,44
In our case, it is not clear if the development of gummaswas the
result of unsuccessful treatment of prior syphilis or acquisition of a
new infection. Treatment guidelines for syphilis in HIV-positive
patients remain controversial with conﬂicting evidence for the
beneﬁt of extended therapy.21,45,46 Several studies have shown
higher rates of serologically deﬁned treatment failures for syphilis
ranging from 14% to 39% in HIV-infected individuals compared to
HIV-negative controls.21,24,47–49 In view of this, prior treatment for
syphilis may not guarantee cure in HIV-positive individuals and
recurrent or tertiary disease should be considered irrespective of
treatment history. Ongoing clinical and serologic follow-up is
advisable.
Rates of syphilis remain high in many developing countries and
are increasing in industrialized nations, particularly among MSM.
The reciprocal effects of syphilis and HIV on transmission and
disease progression should raise concern as these epidemics
M. McVey et al. / International Journal of Infectious Diseases 14S (2010) e283–e286e286converge. HIV co-infection often results inmore aggressive disease
due to syphilis and can lead to faster progression to tertiary
symptoms with increased risk for neurological complications such
as gummas. Given the broad differential for HIV-positive patients
presenting with neurological symptoms, the clinician must
maintain a high index of suspicion for syphilis, known for its
varied manifestations. Gummatous neurosyphilis is a rare
presentation, even among HIV-positive patients, but this case
demonstrates the importance of considering gummas among
patients who present with neurological ﬁndings.
Conﬂict of interest: The authors have no conﬂicts of interest
related to this work.
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